Energysquare, a French wireless charging company, raised €3M in funding.
Alkemics, a Paris, France-based platform enabling brands to launch products with retailers, raised €21m in Series C funding round.
Ambler, a French provider of a platform to handle inter-hospital patient transfers, raised €6M in funding.
Servier, a Paris, France-based independent international pharmaceutical company, completed the acquisition of Symphogen A/S.
Accenture (NYSE: ACN) has completed the acquisition of Gekko, a French Amazon Web Services (AWS) cloud services company.
Tollys, a Lyon, France-based developer of a synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, closed a Series A round of financing totaling €2.3m ($2.5M).
UroMems, a Grenoble, France-based developer and manufacturer of the electronic artificial urinary sphincter (eAUS), raised €16m in a combination of equity and debt financing.
Contentsquare, a Paris, France- and NYC-based provider of an experience analytics platform, raised $190m in Series D funding.
PlanetWatch, a St. Genis-Pouilly, France-based blockchain powered cleantech startup, raised €550k in funding.
PlayPlay, a French company that provides a video creation tool that enables comms, marketing and social media teams to produce high-quality videos in minutes, raised €10m in Series A funding.
AXA Venture Partners, a venture capital firm investing in high-growth technology companies, completed a €200m first closing of AVP Diversified II, the second vintage of AVP Fund of Funds strategy.
Pricefx, a Munich, Germany-based provider of native cloud pricing software, acquired Brennus Analytics, an AI pricing software startup based in France.
InsideBoard, a Paris, France-based provider of a SaaS platform for organizational change management based on Artificial Intelligence, raised €25m in Series B funding round.
Robocath, a Rouen, France-based company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, secured €40m ($43M) in series C financing.
Asklepios BioPharmaceutical, Inc., a Research Triangle Park, NC-based clinical-stage adeno-associated virus (AAV) gene therapy company, acquired BrainVectis, a Paris, France-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders.